Paper Details

  1. Home
  2. Paper Details

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.

Author: Carvajal-AlegriaGuillermo, Chary-ValckenaereIsabelle, ChicheLaurent, CornecDivi, DernisEmmanuelle, DervieuxBenjamin, Devauchelle-PensecValérie, DirezGuillaume, FautrelBruno Jean, FeltenRenaud, GottenbergJacques-Eric, GuellecDewi, HilliquinPascal, Le HenaffCatherine, MarhadourThierry, NowakEmmanuel, PerdrigerAleth, RichezChristophe, SarauxAlain, ToussirotEric, TruchetetMarie-Elise, WendlingDaniel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This double-blind, placebo-controlled randomized clinical trial of 101 patients with active polymyalgia rheumatica despite prednisone therapy found that tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with reduced prednisone requirements.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica. OBJECTIVE: To compare the efficacy of tocilizumab vs placebo in patients ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.2022.15459

データ提供：米国国立医学図書館（NLM）

Tocilizumab: A Potential Oasis for Glucocorticoid-Dependent Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) is a painful inflammatory condition that primarily affects the muscles and joints. This research explores the effectiveness of tocilizumab, an interleukin-6 (IL-6) antagonist, in reducing disease activity in patients with glucocorticoid-dependent PMR. The researchers conducted a randomized clinical trial comparing tocilizumab to placebo in patients with active PMR who were dependent on prednisone. They aimed to evaluate the efficacy of tocilizumab in reducing disease activity, enabling prednisone dose reduction, and improving overall well-being.

Tocilizumab's Effectiveness: A Promising Finding

The study found that tocilizumab significantly improved disease activity in patients with glucocorticoid-dependent PMR, leading to a greater percentage of patients achieving a lower C-reactive protein level (CRP) and reduced prednisone requirements. This encouraging finding suggests that tocilizumab could be a valuable treatment option for patients with PMR, helping to reduce reliance on prednisone and improving overall well-being.

Hope on the Horizon: A New Tool for PMR Management

This research offers a promising new treatment option for patients with PMR. Tocilizumab's effectiveness in reducing disease activity and enabling prednisone dose reduction could significantly improve the quality of life for these patients. This research underscores the importance of continuous exploration and innovation in seeking better treatment options for inflammatory conditions.

Dr.Camel's Conclusion

Just as a camel finds respite in an oasis, tocilizumab offers a potential oasis for patients with glucocorticoid-dependent PMR. This study highlights the importance of exploring new treatments for chronic inflammatory conditions, providing hope for a better future for those seeking relief from the debilitating symptoms of PMR.

Date :
  1. Date Completed 2022-09-23
  2. Date Revised 2023-01-31
Further Info :

Pubmed ID

36125471

DOI: Digital Object Identifier

10.1001/jama.2022.15459

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.